For Canadian investors navigating today’s market, geographic diversification is often part of the conversation. That’s especially true in healthcare — a sector shaped by global innovation and aging populations. While many portfolios tend to favour U.S. healthcare giants, some investors are increasingly looking beyond the U.S. for exposure to medical research and development happening in other parts of the world.
Why Global Exposure is Important
In fluctuating markets, geographic diversification tends to be used to help manage concentration risk. While healthcare is generally viewed as less cyclical than other sectors, regional dynamics and local policy changes still impact performance.
European healthcare companies often operate within:
- Public healthcare systems that may support consistent demand.
- Specialized therapeutic areas, including metabolic disease and oncology.
- Different currency environments, which may serve to buffer North American market volatility.
A Potential Approach to Global Healthcare Exposure
The Global X Equal Weight Global Healthcare Index ETF (MEDX:TSX) aims to provide streamlined access to various healthcare companies. As of April 29, 2026 U.S. firms represent the majority of the portfolio (70.35%), while approximately 25% is allocated to non-U.S. equities — a segment that includes several European pharmaceutical organizations.
This structure is intended to position MEDX as a one-ticket option for Canadians seeking global exposure. Instead of managing multiple foreign exchange transactions or various tax complexities, this vehicle allows for access to a diversified basket of healthcare entities directly on the TSX.
As of April 29, 2026 the ETF’s international allocation includes several global healthcare organizations:
- Novo Nordisk A/S (5%): Based in Denmark, this company focuses on diabetes care and metabolic health markets.
- AstraZeneca PLC (5%): AstraZeneca is a British-Swedish multinational biopharmaceutical company that discovers, develops, and commercializes innovative prescription medicines, with a major strategic focus on oncology, rare diseases, and biopharmaceuticals for cardiovascular, renal, and respiratory conditions.
- Novartis AG (5%) and Roche Holding AG (5%): Swiss-based entities that focus on oncology, diagnostics, and therapeutics.
These firms represent geographic diversification and provide exposure to different regulatory environments and research ecosystems.
By incorporating these elements, MEDX seeks to provide exposure to the broader healthcare landscape.
For Canadian investors, accessing international healthcare organizations has historically involved various levels of complexity. Vehicles such as MEDX are designed to provide access to global equities within a single structure. With a portion of its portfolio dedicated to global equities, the ETF provides a way to access several healthcare companies. In a sector where research and development occur globally, this broader exposure may be relevant to investors.
Commissions, management fees and expenses all may be associated with an investment in products (the “Global X Funds”) managed by Global X Investments Canada Inc. The Global X Funds are not guaranteed, their values change frequently and past performance may not be repeated. The prospectus contains important detailed information about the Global X Funds. Please read the relevant prospectus before investing.
Certain statements may constitute a forward-looking statement, including those identified by the expression “expect” and similar expressions (including grammatical variations thereof). The forward-looking statements are not historical facts but reflect the author’s current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking statements. These forward-looking statements are made as of the date hereof and the authors do not undertake to update any forward-looking statement that is contained herein, whether as a result of new information, future events or otherwise, unless required by applicable law.
This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase investment products (the “Global X Funds”) managed by Global X Investments Canada Inc. and is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard. Individuals should seek the advice of professionals, as appropriate, regarding any particular investment. Investors should consult their professional advisors prior to implementing any changes to their investment strategies. These investments may not be suitable to the circumstances of an investor.
Global X Investments Canada Inc. (“Global X”) is a wholly-owned subsidiary of Mirae Asset Global Investments Co., Ltd. (“Mirae Asset”), the Korea-based asset management entity of Mirae Asset Financial Group. Global X is a corporation existing under the laws of Canada and is the manager, investment manager and trustee of the Global X Funds.
© 2026 Global X Investments Canada Inc. All Rights Reserved.